Heterocyclic-fused 3(2H)-pyridazinones as potent and selective PDE IV inhibitors: Further structure-activity relationships and molecular modelling studies

European Journal of Medicinal Chemistry

Volumn 33, Issue 10, 1998, Pages 789-797

  Dal Piaz, Vittorio ^a   Giovannoni, Maria Paola ^a   Castellana, Carla ^a   Palacios, José Maria ^b   Beleta, Jorge ^b   Doménech, Teresa ^b   Segarra, Victor ^b  

^a Dipto di Scienze Farmaceutiche   (Italy)

^b Research Center ^*  (Spain)

Author keywords

Heterocyclic fused pyridazinones; Phosphodiesterase IV inhibitory activity

Indexed keywords

PHOSPHODIESTERASE IV INHIBITOR; PYRIDAZINONE DERIVATIVE; ROLIPRAM;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG POTENCY; HYDROGEN BOND; MOLECULAR MODEL; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

EID: 0032311447     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(99)80030-0     Document Type: Article

References (29)

1. [ 1] Palfreyman M.N., Souness J.E., In: Ellis G.P., Luscombe D.K. (Eds.), Progress in Medicinal Chemistry, Elsevier, Amsterdam, 1996, pp. 1-52.
2. [2] Lombardo L.J., Curr. Pharmacol. Des. 1 (1995) 255-268.
3. [3] Palacios J.M., Beleta J., Segarra V., Il Farmaco 50 (1995) 819-827.
4. [4] Stafford J.A., Feldman P.L., Ann. Rep. Med. Chem. 31 (1996) 71-80.
5. [5] Laitinen L.A., Laitinen A., Haahtela T., Amer. Rev. Respir. Dis. 147 (1993) 679-704.
6. [6] Whelan C.J., Drugs Today 32 (1996) 295-311.
7. [7] Schwabe U., Miyake M., Ohga Y., Daly J.W., Mol. Pharmacol. 12 (1976) 900-910.
8. [8] Soaness J.E., Roo S., Cell Signal., in press.
9. [9] Masamune H., Cheng J.B., Cooper K., Eggler J.F., Marfat A., Marshall S.C., Shirley J.T., Tickner J.E., Umland J.P., Vazquez E., Bioorg. Med. Chem. Lett. 5 (1995) 1965-1968.
10. [10] Cheng J.B., Cooper K., Duplantier A.J., Eggler J.F., Kraus K.G., Marshall S.C., Marfat A., Masamune H., Shirley J.T., Tickner J.E., Umland J.E., Bioorg. Med. Chem. Lett. 5 (1995) 1969-1972.
11. [11] (a) Dal Piaz V., Giovannoni M.P., Castellana C., Palacios J., Beleta J., Domenech T., Segarra V., J. Med. Chem. 40 (1997) 1417-1421;
12. (b) Dal Piaz V et al., Drug Discovery Today 2 (1997) 351-352.
13. [12] Alvarez R., Daniels D.V., Shelton P.S., Baecker P.S., Fong T.A.T., Devens B., Wilhelm R., Eglen R.M., Cont M., Phosphodiesterase Inhibitors, Academic Press, London, 1996, pp. 161-171.
14. [13] Whilhelm R., Loe B., Alvarez R., Devens B., Fong A., P-32, 8th RSC-SCI Medicinal Chemistry Symposium, Cambridge, UK, 10-13 September 1995.
15. [14] Chantegrel B., Deshayes C., Pujol B., J. Heterocyclic Chem. 27 (1990) 927-934.
16. [15] Dal Piaz V., Giovannoni M.P., Ciciani G., Franconi F., Drug Des. Discov. 14 (1996) 53-75.
17. [16] Dal Piaz V., Ciciani G., Giovannoni M.P., Synthesis (1994) 669-671.
18. [17] Gristwood R.W., Beleta J., Bou J., Cardelus I., Fernandez A.G., Lenas J., Berga P., Br. J. Pharmacol. 105 (1992) 985-991.
19. [18] Thompson W.J., Strada S.J., In: Bergmayer H.U. (Ed.), Method of Enzymatic Analysis, Vol. IV, 3rd ed., Chemie-Verlag, Weinheim, 1984, pp. 127-134.
20. [19] Schneider H.H., Schmiechen R., Brezinski M., Seidler J., Eur. J. Pharmacol. 127 (1986) 105-115.
21. [20] Chem-X, version January 97, Chemical Design Limited, Oxfordshire 0X7 5SR, England.
22. [21] Davies E.K., Murrall N.W., Comput. Chem. 13 (1989) 149-156.
23. [22] MOPAC/AM1 (Program no. 506, version 6.0, Quantum Chemistry Program Exchange, QCPE, Bloomington, IN, USA).
24. [23] Stewart J.P.J., J. Comput. Aided Mol. Des. 4 (1990) 1-105.
25. [24] GRID, version 15, Molecular Discovery Limited, Oxford OX2 9LL, England.
26. [25] Goodford P.J., J. Med. Chem. 28 (1985) 849-857.
27. [26] Wade R.C., Clark K.J., Goodford P.J., J. Med. Chem. 36 (1993)140-147.
28. [27] Wade R.C., Goodford P.J., J. Med. Chem. 36 (1993) 148-156.
29. [28] Boobbyer D.N.A., Goodford P.J., McWhinnie P.M., Wade R.C., J. Med. Chem. 32 (1989) 1083-1094.